Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


16.10.2017

1 BMJ
11 Clin Infect Dis
1 Infect Immun
1 J Immunol
1 J Infect
2 J Virol
1 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 Pediatr Infect Dis J
2 Pediatrics
9 PLoS One
9 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMJ

  1. IACOBUCCI G
    General practice threatens to withhold repeat prescriptions until patients have flu vaccine.
    BMJ. 2017;359:j4682.
    PubMed     Text format    


    Clin Infect Dis

  2. PILLSBURY AJ, Quinn HE, Evans TD, McIntyre PB, et al
    Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
    Clin Infect Dis. 2017;65:827-832.
    PubMed     Text format     Abstract available

  3. VAN DEURSEN AMM, van Houten MA, Webber C, Patton M, et al
    Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Clin Infect Dis. 2017;65:787-795.
    PubMed     Text format     Abstract available

  4. MCNAMARA LA, Skoff T, Faulkner A, Miller L, et al
    Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012.
    Clin Infect Dis. 2017;65:811-818.
    PubMed     Text format     Abstract available

  5. PETRIE JG, Malosh RE, Cheng CK, Ohmit SE, et al
    The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.
    Clin Infect Dis. 2017 Jul 20. doi: 10.1093.
    PubMed     Text format     Abstract available

  6. WARREN JL, Shioda K, Kurum E, Schuck-Paim C, et al
    Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.
    Clin Infect Dis. 2017 Jul 22. doi: 10.1093.
    PubMed     Text format     Abstract available

  7. LEWNARD JA, Givon-Lavi N, Weinberger DM, Lipsitch M, et al
    Pan-serotype reduction in progression of Streptococcus pneumoniae to otitis media after rollout of pneumococcal conjugate vaccines.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    PubMed     Text format     Abstract available

  8. HEATH G, Depledge DP, Brown JR, Hale AD, et al
    Acute Retinal Necrosis caused by the zoster vaccine virus.
    Clin Infect Dis. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available

  9. LEE YJ, Huang YT, Kim SJ, Kerpelev M, et al
    Trends in invasive pneumococcal disease (IPD) in cancer patients after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7): A 20-year longitudinal study at a major urban cancer center.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    PubMed     Text format     Abstract available

  10. SHAH M, Quinlisk P, Weigel A, Riley J, et al
    Mumps outbreak in a highly vaccinated university-affiliated setting before and after a measles-mumps-rubella (MMR) vaccination campaign-Iowa, July 2015-May 2016.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available

  11. YANG Y, Meng Y, Halloran ME, Longini IM Jr, et al
    Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available

  12. PIROTH L, Launay O, Miailhes P, Carrat F, et al
    Isolated anti-HBc serological profile: has the time come to vaccinate?
    Clin Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format    


    Infect Immun

  13. PARZYCH EM, Miura K, Ramanathan A, Long CA, et al
    Evaluation of a Plasmodium-specific carrier protein to enhance production of recombinant Pfs25, a leading transmission-blocking vaccine candidate.
    Infect Immun. 2017 Oct 9. pii: IAI.00486-17. doi: 10.1128/IAI.00486.
    PubMed     Text format     Abstract available


    J Immunol

  14. MUKHOPADHYAY M, Galperin M, Patgaonkar M, Vasan S, et al
    DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.
    J Immunol. 2017 Oct 9. pii: ji1700953. doi: 10.4049/jimmunol.1700953.
    PubMed     Text format     Abstract available


    J Infect

  15. ABAD R, Medina V, Farinas MDC, Martinez-Martinez L, et al
    Potential impact of the 4CMenB vaccine on oropharyngeal carriage of neisseria meningitidis.
    J Infect. 2017 Oct 5. pii: S0163-4453(17)30313.
    PubMed     Text format     Abstract available


    J Virol

  16. MCGUIRE EP, Fong Y, Toote C, Cunningham CK, et al
    HIV exposed infants vaccinated with a MF59/rgp120 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01070-17. doi: 10.1128/JVI.01070.
    PubMed     Text format     Abstract available

  17. SHEN X, Basu R, Sawant S, Beaumont D, et al
    HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01077-17. doi: 10.1128/JVI.01077.
    PubMed     Text format     Abstract available


    MMWR Morb Mortal Wkly Rep

  18. SEITHER R, Calhoun K, Street EJ, Mellerson J, et al
    Vaccination Coverage for Selected Vaccines, Exemption Rates, and Provisional Enrollment Among Children in Kindergarten - United States, 2016-17 School Year.
    MMWR Morb Mortal Wkly Rep. 2017;66:1073-1080.
    PubMed     Text format     Abstract available


    N Engl J Med

  19. SCHRICK L, Tausch SH, Dabrowski PW, Damaso CR, et al
    An Early American Smallpox Vaccine Based on Horsepox.
    N Engl J Med. 2017;377:1491-1492.
    PubMed     Text format    

  20. KENNEDY SB, Bolay F, Kieh M, Grandits G, et al
    Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
    N Engl J Med. 2017;377:1438-1447.
    PubMed     Text format     Abstract available


    Pediatr Infect Dis J

  21. LIVNI G, Wainstein A, Birk E, Chodick G, et al
    Influenza Vaccination Rate and Reasons for Nonvaccination in Children With Cardiac Disease.
    Pediatr Infect Dis J. 2017;36:e268-e271.
    PubMed     Text format     Abstract available


    Pediatrics


  22. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018.
    Pediatrics. 2017 Sep 4. pii: e20172550. doi: 10.1542/peds.2017-2550.
    PubMed     Text format     Abstract available

  23. ROBISON SG, Dunn AG, Richards DL, Leman RF, et al
    Changes in Influenza Vaccination Rates After Withdrawal of Live Vaccine.
    Pediatrics. 2017 Oct 6. pii: e20170516. doi: 10.1542/peds.2017-0516.
    PubMed     Text format     Abstract available


    PLoS One

  24. HASSAN AO, Amen O, Sayedahmed EE, Vemula SV, et al
    Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.
    PLoS One. 2017;12:e0186244.
    PubMed     Text format     Abstract available

  25. FERREYRA-REYES L, Cruz-Hervert LP, Troy SB, Huang C, et al
    Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico.
    PLoS One. 2017;12:e0185594.
    PubMed     Text format     Abstract available

  26. MAILYBAYEVA A, Yespembetov B, Ryskeldinova S, Zinina N, et al
    Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
    PLoS One. 2017;12:e0186484.
    PubMed     Text format     Abstract available

  27. WARD PR, Attwell K, Meyer SB, Rokkas P, et al
    Understanding the perceived logic of care by vaccine-hesitant and vaccine-refusing parents: A qualitative study in Australia.
    PLoS One. 2017;12:e0185955.
    PubMed     Text format     Abstract available

  28. BILLARD MN, De Serres G, Gariepy MC, Boulianne N, et al
    Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.
    PLoS One. 2017;12:e0186070.
    PubMed     Text format     Abstract available

  29. MCCURLEY NP, Domi A, Basu R, Saunders KO, et al
    HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
    PLoS One. 2017;12:e0177863.
    PubMed     Text format     Abstract available

  30. SMITH SG, Harris SA, Satti I, Bryan D, et al
    Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials.
    PLoS One. 2017;12:e0184391.
    PubMed     Text format     Abstract available

  31. BOTWRIGHT S, Holroyd T, Nanda S, Bloem P, et al
    Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
    PLoS One. 2017;12:e0182663.
    PubMed     Text format     Abstract available

  32. GIANINO MM, Politano G, Scarmozzino A, Charrier L, et al
    Estimation of sickness absenteeism among Italian healthcare workers during seasonal influenza epidemics.
    PLoS One. 2017;12:e0182510.
    PubMed     Text format     Abstract available


    Vaccine

  33. GESSNER BD, Kaslow D, Louis J, Neuzil K, et al
    Estimating the full public health value of vaccination.
    Vaccine. 2017 Oct 3. pii: S0264-410X(17)31296.
    PubMed     Text format     Abstract available

  34. SUN P, Crum-Cianflone NF, Defang G, Williams M, et al
    Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307.
    PubMed     Text format     Abstract available

  35. SUN J, Li M, Wang Y, Hao P, et al
    Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31316.
    PubMed     Text format     Abstract available

  36. PARRISH-SPROWL J
    Vaccine hesitancy communication: What counts as evidence.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31317.
    PubMed     Text format     Abstract available

  37. WALKER RI, Wierzba TF, Mani S, Bourgeois AL, et al
    Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31274.
    PubMed     Text format     Abstract available

  38. OFORI-ANYINAM O, Leroux-Roels G, Drame M, Aerssens A, et al
    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >/=50years of age: Results from a phase III, randomized, non-i
    Vaccine. 2017 Oct 5. pii: S0264-410X(17)31228.
    PubMed     Text format     Abstract available

  39. MARTINELLI D, Azzari C, Bonanni P, Esposito S, et al
    Impact of Haemophilus influenzae type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy.
    Vaccine. 2017 Oct 5. pii: S0264-410X(17)31330.
    PubMed     Text format     Abstract available

  40. KRACALIK I, Malania L, Broladze M, Navdarashvili A, et al
    Changing livestock vaccination policy alters the epidemiology of human anthrax, Georgia, 2000-2013.
    Vaccine. 2017 Oct 5. pii: S0264-410X(17)31334.
    PubMed     Text format     Abstract available

  41. PILEGGI C, Papadopoli R, Bianco A, Pavia M, et al
    Hepatitis B vaccine and the need for a booster dose after primary vaccination.
    Vaccine. 2017 Oct 5. pii: S0264-410X(17)31329.
    PubMed     Text format     Abstract available


    Virology

  42. MARTINS M, Joshi LR, Rodrigues FS, Anziliero D, et al
    Immunogenicity of ORFV-based vectors expressing the rabies virus glycoprotein in livestock species.
    Virology. 2017;511:229-239.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: